Quiz

Multiple Sclerosis

Multiple Sclerosis Lecture Series: Treatment

Name: Multiple Sclerosis Lecture Series: Treatment
Uploaded: 5/16/2023
Duration: T36M35S
Description: Watch the fourth lecture in the MS Series to learn about how to choose disease-modifying treatment options, the importance of monitoring patients at regular intervals to evaluate signs of disease activity, and how to balance patients' risks and comorbidities with the advantages of treatments.

Learning Objectives
1. Summarize the benefits of early, high-efficacy treatments for multiple sclerosis
2. Implement consistent disease activity and safety monitoring into clinical practice

0.5 Credit CME

Stanford Medicine

Activity Information and Disclosures

Published Online: May 16, 2023 Video 36 min 35 sec

Watch Take Quiz

Internet Enduring Material sponsored by Stanford University School of Medicine. Presented by the Stanford University School of Medicine Department of Neurology and Center for Continuing Medical Education.

How can providers best provide timely treatment to Multiple Sclerosis patients? Watch the fourth lecture in the MS Series to learn about how to choose disease-modifying treatment options, the importance of monitoring patients at regular intervals to evaluate signs of disease activity, and how to balance patients' risks and comorbidities with the advantages of treatments. Listen in to examine the available data about treating with the escalation approach or early induction approach.

Take Quiz

Video Information

All Rights Reserved. The content of this activity is protected by U.S. and International copyright laws. Reproduction and distribution of its content without written permission of its creator(s) is prohibited.

Accreditation

In support of improving patient care, Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Financial Support Disclosure Statement: Stanford Medicine adheres to the Standards for Integrity and Independence in Accredited Continuing Education.

There are no relevant financial relationships with ACCME-defined ineligible companies for anyone who was in control of the content of this activity, except those listed in the table below. All of the relevant financial relationships listed for these individuals have been mitigated.

Lucas B. Kipp, MD

Stanford hospital & Clinics

Course Director, Faculty

Grant or research support-Roche/Genetech/ Grant or research support biogen Idec.

Ruth Adewuya, MD, CHCP

Managing Director, Center for Continuing Medical Education

Stanford University School of Medicine

Planner

Nothing to disclose

Marilyn Mejia, BA

Education Design Coordinator

Stanford University

Planner

Nothing to disclose.

Jamie McDonald, MD

Stanford Health Care

Reviewer

Nothing to disclose

Commercial Support Disclosure Statement: This educational activity is supported in part by an educational grant from Novartis Pharmaceuticals Corporation.

References:

National Multiple Sclerosis Society. Ask an MS Navigator. Accessed June 3, 2022. https://www.nationalmssociety.org/Resources-Support/Find-Support/Ask-an-MS-Navigator

Bergamaschi R. Prognostic factors in multiple sclerosis. Int Rev Neurobiol. 2007;79:423–447. doi:10.1016/S0074-7742(07)79019-0 Google Scholar

Berger JR. Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord. 2017;12:59–63. doi:10.1016/j.msard.2017.01.006 Google Scholar

Bose G, Freedman MS. Precision medicine in the multiple sclerosis clinic: Selecting the right patient for the right treatment. Multiple Sclerosis Journal. 2020;26(5):540–547. doi:10.1177/1352458519887324 Google Scholar

Brown JWL, Coles A, Horakova D, et al. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis [published correction appears in JAMA. 2020 Apr 7;323(13):1318]. JAMA. 2019;321(2):175–187. doi:10.1001/jama.2018.20588 Google Scholar

Burton JM, O'Connor PW, Hohol M, Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev. 2012;12:CD006921. Published 2012 Dec 12 . doi:10.1002/14651858.CD006921.pub3 Google Scholar

Coles Alasdair, . Newer therapies for multiple sclerosis. Annals of Indian Academy of Neurology18(Suppl 1):p S30–S34, September 2015. DOI: 10.4103/0972-2327.164824 Google Scholar

Dobson R, Giovannoni G. Multiple sclerosis - a review. Eur J Neurol. 2019;26(1):27–40. doi:10.1111/ene.13819 Google Scholar

Fig. 1: Timeline of Developments in the Treatment of Multiple Sclerosis. | Nature Reviews Neurology. Accessed June 3, 2022. https://www.nature.com/articles/s41582-018-0082-z/figures/1 Google Scholar

10.

Gasperini C, Prosperini L, Tintoré M, et al. Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge. Neurology. 2019;92(4):180–192. doi:10.1212/WNL.0000000000006810 Google Scholar

11.

Giovannoni G, Butzkueven H, Dhib-Jalbut S, et al. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016;9 Suppl 1:S5–S48. doi:10.1016/j.msard.2016.07.003 Google Scholar

12.

Gross RH, Corboy JR. Monitoring, Switching, and Stopping Multiple Sclerosis Disease-Modifying Therapies [published correction appears in Continuum (Minneap Minn). 2019 Aug;25(4):1175]. Continuum (Minneap Minn). 2019;25(3):715–735. doi:10.1212/CON.0000000000000738 Google Scholar

13.

Harding K, Williams O, Willis M, et al. Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis. JAMA Neurol. 2019;76(5):536–541. doi:10.1001/jamaneurol.2018.4905 Google Scholar

14.

Le Page E, Veillard D, Laplaud DA, et al. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial [published correction appears in Lancet. 2016 Jan 23;387(10016):340]. Lancet. 2015;386(9997):974–981. doi:10.1016/S0140-6736(15)61137-0 Google Scholar

15.

Luna G, Alping P, Burman J, et al. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies [published correction appears in JAMA Neurol. 2021 Sep 7;:null ]. JAMA Neurol. 2020;77(2):184–191. doi:10.1001/jamaneurol.2019.3365 Google Scholar

16.

Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology [published correction appears in Neurology. 2019 Jan 8;92(2):112]. Neurology. 2018;90(17):777–788. doi:10.1212/WNL.0000000000005347 Google Scholar

17.

Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2015;72(2):152–158. doi:10.1001/jamaneurol.2014.3537 Google Scholar

18.

Spelman T, Magyari M, Piehl F, et al. Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies. JAMA Neurol. 2021;78(10):1197–1204. doi:10.1001/jamaneurol.2021.2738 Google Scholar

19.

Sriwastava S, Kataria S, Srivastava S, et al. Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis. J Neuroimmunol. 2021;360:577721. doi:10.1016/j.jneuroim.2021.577721 Google Scholar

Accreditation
In support of improving patient care, Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation
Stanford Medicine designates this Enduring Material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Multiple Sclerosis Lecture Series: Treatment

AMA Membership provides:

Sign in to access

Sign in to customize your interests

Name Your Search

Sign in to save your search

Lookup An Activity

My Saved Searches

My Saved Courses

Purchase access